$444.86 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter

Brokerages expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to announce $444.86 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for BioMarin Pharmaceutical’s earnings. The lowest sales estimate is $412.21 million and the highest is $482.40 million. BioMarin Pharmaceutical reported sales of $502.07 million in the same quarter last year, which indicates a negative year-over-year growth rate of 11.4%. The firm is scheduled to announce its next earnings results on Wednesday, May 5th.

According to Zacks, analysts expect that BioMarin Pharmaceutical will report full-year sales of $1.82 billion for the current financial year, with estimates ranging from $1.75 billion to $1.90 billion. For the next fiscal year, analysts forecast that the business will post sales of $2.19 billion, with estimates ranging from $1.87 billion to $2.41 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, February 25th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.18. BioMarin Pharmaceutical had a net margin of 45.74% and a return on equity of 4.34%. The firm had revenue of $452.12 million during the quarter, compared to analyst estimates of $447.17 million.

Several research firms have recently weighed in on BMRN. Evercore ISI upgraded shares of BioMarin Pharmaceutical from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $90.00 to $100.00 in a research note on Monday, March 8th. Canaccord Genuity reduced their price target on shares of BioMarin Pharmaceutical from $95.00 to $91.00 and set a “buy” rating for the company in a research report on Monday, March 8th. Robert W. Baird reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Monday, March 1st. Finally, Wedbush reissued an “outperform” rating and issued a $139.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, March 23rd. Eight equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $117.87.

In related news, CFO Brian Mueller sold 5,692 shares of the company’s stock in a transaction that occurred on Thursday, April 1st. The stock was sold at an average price of $76.30, for a total transaction of $434,299.60. Following the completion of the transaction, the chief financial officer now owns 31,016 shares in the company, valued at $2,366,520.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jean Jacques Bienaime sold 8,334 shares of the stock in a transaction on Friday, January 29th. The stock was sold at an average price of $82.67, for a total value of $688,971.78. Following the completion of the transaction, the chief executive officer now owns 303,885 shares of the company’s stock, valued at approximately $25,122,172.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,385 shares of company stock valued at $4,335,452. Insiders own 2.15% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Westside Investment Management Inc. bought a new position in BioMarin Pharmaceutical in the fourth quarter worth $31,000. Freedman Financial Associates Inc. bought a new position in BioMarin Pharmaceutical in the fourth quarter worth $33,000. Steward Partners Investment Advisory LLC raised its holdings in BioMarin Pharmaceutical by 189.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 425 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 278 shares in the last quarter. Ellevest Inc. increased its holdings in shares of BioMarin Pharmaceutical by 284.6% during the fourth quarter. Ellevest Inc. now owns 450 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 333 shares in the last quarter. Finally, CKW Financial Group increased its holdings in shares of BioMarin Pharmaceutical by 80.0% during the fourth quarter. CKW Financial Group now owns 450 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 97.65% of the company’s stock.

Shares of NASDAQ:BMRN traded down $0.12 during mid-day trading on Friday, hitting $76.95. The company had a trading volume of 11,670 shares, compared to its average volume of 1,326,864. The firm has a fifty day moving average price of $77.98 and a 200 day moving average price of $80.45. The company has a market capitalization of $13.99 billion, a PE ratio of 17.64, a price-to-earnings-growth ratio of 3.89 and a beta of 0.71. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.20 and a quick ratio of 2.38. BioMarin Pharmaceutical has a one year low of $71.35 and a one year high of $131.95.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Story: How to start trading in the forex market?

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.